Extended follow-up of AMBASSADOR: adjuvant pembrolizumab in MIUC

Описание к видео Extended follow-up of AMBASSADOR: adjuvant pembrolizumab in MIUC

Andrea Apolo, MD, National Cancer Institute, Bethesda, MD, comments on the extended follow-up disease-free survival (DFS) results from the Phase III AMBASSADOR trial (NCT03244384) of adjuvant pembrolizumab in patients with muscle-invasive and locally advanced urothelial carcinoma (MIUC) of the bladder. Pembrolizumab was found to continue to be superior in terms of DFS. This interview took place at the European Society for Medical Oncology (ESMO) 2024 Congress in Barcelona, Spain.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Комментарии

Информация по комментариям в разработке